Background: Synapsin II regulates neurotransmitter release from mature nerve terminals
and plays important role in the formation of new nerve terminals. The associations of SYN II are
identified in various studies that are linked to the onset of Schizophrenia. Schizophrenia is characterized
by abnormal behavior like obsession, dampening of emotions and auditory hallucination.
Methods: The bioinformatics approaches were utilized for structural modeling and docking analyses
of SYN II followed by pharmacophore generation to identify potent inhibitors.
Results: The comparative modeling approach was employed to generate the 3D model having
82.404% quality factor calculated by Errat. Pharmacophore was constructed by utilizing merge
molecular and chemical features of selected five FDA approved Schizophrenia drugs by
LigandScout 4.1.5. Comparative docking analyses were performed by utilizing the selected drugs
and top screened hits by GOLD and AutoDock Vina.
Conclusion: It was proposed that Aripiprazole drug and scrutinized compounds have strong binding
affinities among the other selected drugs. The reported compounds may be used for further analyses
in the drug discovery processes, as they have shown good human intestinal absorption and are noncarcinogenic.
The present study provides the structural insights which may be used for further
understating of the Schizophrenia therapeutic purposes by targeting SYN II and other inhibitors